NCT05054387View on ClinicalTrials.gov

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Fabry Disease
Interventions
DRUG

Agalsidase beta

Powder for concentration into a solution Intravenous (IV) infusion

Trial Locations (6)

100034

Investigational Site Number :1560003, Beijing

100730

Investigational Site Number :1560002, Beijing

200025

Investigational Site Number :1560001, Shanghai

201102

Investigational Site Number :1560004, Shanghai

030001

Investigational Site Number :1560006, Taiyuan

016040

Investigational Site Number :1560005, Wuhan

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT05054387 - China Post-marketing Surveillance (PMS) Study of Fabrazyme® | Biotech Hunter | Biotech Hunter